Background {#Sec1}
==========

Peripheral arterial disease (PAD) is characterized by a narrowing of the arteries in peripheral vessels caused by atherosclerotic plaque formation, resulting in decreased blood flow to distal appendages. This disorder affects 8 to 12 million Americans and represents a significant financial health care burden that will rise concomitantly with the rates of obesity and diabetes \[[@CR1]\]. Critical limb ischemia (CLI), characterized by pain at rest, ulcerations, and/or gangrene in the extremity, is considered an end stage of PAD, with the majority of these patients undergoing revascularization (bypass or angioplasty) or amputation as long as they can tolerate surgery \[[@CR2],[@CR3]\]. Currently, there is no established nonsurgical treatment regimen for CLI patients.

Hydrogen sulfide (H~2~S) plays a number of important roles in cardiovascular physiology as a regulator of inflammation, angiogenesis, vessel tone, and redox potential \[[@CR4]-[@CR6]\]. It has also been shown to be protective in animal models of cardiovascular disease including heart failure \[[@CR7]-[@CR9]\], hypertension \[[@CR10],[@CR11]\], atherosclerosis \[[@CR12],[@CR13]\], and ischemia reperfusion injury in multiple organs and tissues \[[@CR14],[@CR15]\]. Mechanistically, sulfide is thought to mediate these effects in a variety of ways. As a second messenger and signaling molecule, sulfide is thought to modulate cellular function via reversible cysteine s-sulfhydration of a number of enzymes, transcription factors, and cytoskeletal elements \[[@CR16]-[@CR18]\]. Another purported cytoprotective mechanism stems from observations that sulfide at lower concentrations can reversibly reduce the oxygen affinity of cytochrome c oxidase, effectively dampening cellular respiration \[[@CR19],[@CR20]\]. The nucleophilic nature of H~2~S is also thought to contribute to its observed efficacy via the attenuation of oxidative stress and reactive oxygen species (ROS) signaling \[[@CR21]\].

Therapeutic angiogenesis refers to the pharmacologic induction of neovascularization to restore blood flow and oxygenation in ischemic tissue, and published observations suggest hydrogen sulfide could be such a pharmacophore. H~2~S stimulates endothelial cell migration, proliferation, and tube formation in vitro, and has been shown to stimulate vascular growth in the chicken chorioallantoic membrane and into matrigel plugs implanted in vivo in mice \[[@CR5],[@CR22]\]. Furthermore, hydrogen sulfide has been shown to stimulate vascular growth in ischemic heart tissue and improve cardiac function in rodent models of heart failure \[[@CR8],[@CR23]\]. The molecular mechanisms underlying these effects are being investigated, and evidence suggests that H~2~S enhances nitric oxide production and bioavailability \[[@CR24],[@CR25]\], increases HIF-1α mediated gene expression (including VEGF and its receptors) \[[@CR24],[@CR26]\], and can activate VEGFR2 directly via reduction of a vicinal disulfide bond \[[@CR27]\].

To date, several investigators have demonstrated the capacity of hydrogen sulfide to revascularize and restore blood flow to skeletal muscle in rodent models of hindlimb ischemia (HLI). Wang and colleagues used fluorescent microspheres to assess the effect of NaHS on rat hindlimb perfusion, and Bir et al. used laser doppler flowmetry to demonstrate the beneficial effect of Na~2~S on perfusion of the mouse hindlimb \[[@CR24],[@CR28]\]. Both studies provided evidence suggesting that H~2~S mediates these proangiogenic effects via the upregulation of VEGF signaling. In the current study, we sought to determine a minimum dose and schedule of parenteral hydrogen sulfide sufficient to restore perfusion in the rat hindlimb. Utilizing contrast enhanced ultrasound to corroborate laser doppler flowmetry results, we demonstrate here that a twice daily intravenous infusion of 0.25 mg/kg sodium sulfide over as few as 7 days was sufficient to significantly enhance perfusion in the ischemic hindlimb. Moreover, the effect on perfusion persisted several weeks after cessation of treatment.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

Male CD rats, 350--450 g with jugular vein catheters (JVC), were purchased from Charles River (Wilmington, MA). All experiments were approved by the internal Ethical Committee for Animal Care and Use. All animals were singly housed and allowed to acclimate in house for at least 48 hours prior to study entry. The facility was kept at a temperature of 21°C, humidity of 45-55%, under a 12 hour light/dark cycle. Animals had access to food and water *ad libitum*.

Surgical model {#Sec4}
--------------

Under 1.5% isoflurane, animal fur was removed from the distal hind limbs using depilatory cream, and blood flow was measured as described below. An incision was made in the left groin, and the femoral artery was carefully dissected away from the femoral vein, femoral nerve, and surrounding fascia. The femoral artery was ligated at two points with silk suture just distal to the inguinal ligament, and the vessel was then transected between the two ligation points. The incision in the groin was stapled closed, and hind limb blood flow was measured again as described below.

Laser doppler flowmetry {#Sec5}
-----------------------

A laser doppler flow meter (Product\# ML191, ADInstruments, Colorado Springs, CO) was used in conjunction with either a miniature surface flow probe (Product\# MSP300XP, ADInstruments, Colorado Springs, CO) or a fine needle flow probe (Product\# MNP110XP, ADInstruments, Colorado Springs, CO) to measure hind limb blood flow. Blood flow was recorded and analyzed using a PowerLab 8/30 (Product\# ML870/P, Colorado Springs, CO) with LabChart software, and a heat lamp was used to maintain core body temperature while all blood flow measurements were obtained. While under 1.5 % isoflurane, flow measurements were taken from the proximal, medial, and distal portions of each calf twice, for a total of 6 measurements per calf that were averaged to give a single value. Blood flow in the ischemic (left) limb was normalized to blood flow in the nonischemic (right) limb.

Contrast enhanced ultrasound measurements of hindlimb perfusion {#Sec6}
---------------------------------------------------------------

A Vevo 770 high-resolution ultrasound imaging system (VisualSonics, Toronto, Ontario, Canada) equipped with a 15--45 MHz RMV scanhead (Model\# RMV707B, VisualSonics, Toronto, Ontario, Canada) was used to visualize the gastrocnemius and measure perfusion within it. While under 1.5% isoflurane, a lateral section of each gastrocnemius parallel to the fibula was visualized. Once a satisfactory image was obtained, 150 μL of a contrast microbubble solution containing 3.0 x 10^8^ microbubbles were given as a bolus via the jugular vein catheter, and the change in contrast visualized within each gastrocnemius muscle was used to indicate perfusion in the ischemic hindlimb relative to the nonischemic limb. A heat lamp and heated stage were used to maintain core temperature of each animal over the course of measurements.

Immunohistochemical assessment of vascular density and cellular proliferation {#Sec7}
-----------------------------------------------------------------------------

Upon completion of the experimental protocol, each animal was euthanized by exsanguination under 3.0% isoflurane anesthesia. An incision was then made in the left ventricle, and 10% buffered neutral formalin was pushed through the lower torso via the abdominal aorta just proximal to the iliac bifurcation. The left (ischemic) and right (nonischemic) gastrocnemius muscles were then excised and placed in 10% buffered neutral formalin, at which point they were taken to the pathology department at the University of Washington for paraffin embedding, sectioning, and staining.

Six short axis slices of each muscle were embedded into paraffin blocks. For vascular density determination, three sections from each block were stained for CD-31 (PECAM-1), an endothelial specific antigen, and counterstained with hematoxylin. Digital images of 10 high power fields within each section were obtained, and the ratio of PECAM-1 positive vessels to myofibers was quantified for each field.

For determination of cellular proliferation, 3 sections from each block were stained for Ki-67, a nuclear antigen expressed only in proliferating cells. Digital images of 10 high power fields within each section were obtained, and the number of Ki-67 positive nuclei per high power field were determined.

Data analysis {#Sec8}
-------------

All data presented are expressed as the mean + SEM, and all groups were compared using a one way ANOVA with a Bonferroni post hoc test. P \< 0.05 was considered statistically significant.

Results {#Sec9}
=======

Experiment 1 {#Sec10}
------------

In a pilot experiment, four animals were administered sodium sulfide at 1.0 mg/kg (as a one minute i.v. infusion) twice daily for 14 days, while another 4 animals received vehicle (0.9% sodium chloride) at an identical volume twice daily over the same time period. Figure [1](#Fig1){ref-type="fig"} illustrates the effect of femoral artery ligation on hindlimb blood flow measured by laser doppler flowmetry. Panels A and B illustrate the absolute laser doppler blood flow values obtained in the ischemic and nonischemic hindlimbs, respectively, both before and after femoral artery ligation. Panel C compares blood flow in the left hindlimbs before and after left femoral artery ligation in both treatment groups. In this graph, blood flow in the ischemic limb is expressed as a ratio of flow in the nonischemic (right) hind limb. Prior to the onset of ischemia, blood flow in both limbs was comparable (vehicle - 0.97 ± 0.041 vs 1.0 mg/kg sodium sulfide - 0.962 ± 0.033). In the minutes following femoral artery transection, blood flow was reduced in the ischemic limb to approximately 30% of the preischemic value (vehicle -- 0.282 ± 0.023 vs 1.0 mg/kg Na~2~S -- 0.290 ± 0.021). Together, these data demonstrate that the decrease in relative blood flow after the induction of ischemia was strictly due to a decrease in blood flow in the ischemic limb; while blood flow in the nonischemic limb was unaffected.Figure 1Na~2~S Enhances Blood Flow to the Ischemic Hind Limb. Panels **A** and **B** are laser doppler blood flow values obtained from the ischemic and nonischemic hindlimbs, respectively, of rats before and after femoral artery ligation. Panel **C** illustrates changes in blood flow to the ischemic hindlimb minutes after femoral artery ligation, expressed as the ratio of blood flow measured in the ischemic limb (Panel A) vs. the nonischemic limb (Panel B). Panel **D** illustrates the effect of i.v. administration of Na~2~S (1 mg/kg, twice daily) on blood flow in the ischemic hindlimb. \* p \< 0.05 vs Vehicle at respective time point by One Way ANOVA. Values are mean ± SEM.

Panel D of Figure [1](#Fig1){ref-type="fig"} illustrates the effect of i.v. administration of Na~2~S on blood flow recovery in the ischemic hind limb. Sodium sulfide administered at 1.0 mg/kg twice daily significantly elevated blood flow in the ischemic limb by day 7 compared to vehicle treatment and was maintained through day 14. These data are consistent with published results from Bir et al. demonstrating an enhancement of blood flow by day 7 in mice administered sodium sulfide at 1.0 mg/kg twice daily \[[@CR3]\].

After 14 days of treatment, the left and right gastrocnemius muscles from each animal were excised and processed for immunohistochemical assessment of cellular proliferation and vascular density within the tissue. Figure [2](#Fig2){ref-type="fig"} demonstrates the effect of sulfide administration on vascular density and cellular proliferation within the ischemic tissue. In animals receiving a 1.0 mg/kg dose for 14 days, the number of Ki-67 positive nuclei were significantly elevated in the ischemic limb (panels D and E) compared to the nonischemic limb (panels C and E); an effect which was not observed in vehicle treated mice (panels A, B, and E). Similarly, the number of CD-31 positive cells were increased in the ischemic limbs of sulfide treated rats, whereas there was no effect on vascular cell density observed in vehicle treated mice (Panel F).Figure 2Na~2~S Enhances Cellular Proliferation and Vascular Density in the Ischemic Hind Limb. Panels **A** and **B** are representative images of sections with Ki-67-positive nuclei (circled) from nonischemic and ischemic limbs, respectively, of vehicle treated rats. Panels **C** and **D** are representative images from sections of nonischemic and ischemic limbs, respectively, of 1.0 mg/kg Na~2~S treated animals. Panels **E** and **F** are graphs comparing the average number of Ki-67 positive nuclei and PECAM-1 stained vessels for gastrocnemius muscle across treatment groups. \* p \< 0.05 vs Nonischemic of the same treatment group by one way ANOVA. Values are mean ± SEM.

Experiment 2 {#Sec11}
------------

A second study addressed the questions of dose response and minimal effective dosing of sulfide in the model. To these ends, 4 groups of 7 animals received either 1.0 mg/kg, 0.5 mg/kg, 0.25 mg/kg sodium sulfide, or vehicle twice daily for 14 days following the induction of limb ischemia. Laser doppler measurements of blood flow were taken pre- and post-ligation of the femoral artery on day 0, and then once daily on days 1, 3, 5, 7, 10, 12, and 14. All measurements were made with both the fine needle flow probe used in the pilot study, as well as a miniature surface probe. Hindlimb perfusion was also measured on day 14 by contrast ultrasound.

Figure [3](#Fig3){ref-type="fig"} illustrates the effects of twice daily administration of sulfide at these 3 doses on the recovery of blood flow in the ischemic hindlimb. Panels A and B display laser doppler measurements obtained with the miniature surface and fine needle flow probes, respectively. These results demonstrate that sodium sulfide at 0.25, 0.5, and 1.0 mg/kg doses significantly enhanced blood flow to the ischemic hindlimb by day 7, and this elevation was maintained through day 14. These results were consistent with those of the initial pilot, and suggested a 4-fold lower efficacious dose.Figure 3Twice Daily Administration of Na~2~S Enhances Ischemic Limb Perfusion at Doses as Low as 0.25 mg/kg. Panels **A** and **B** illustrate laser doppler blood flow measurements in the ischemic hindlimbs of rats given vehicle or Na~2~S (0.25, 0.5, or 1.0 mg/kg) i.v. twice daily for 14 days. Results in panels **A** and **B** were obtained with a miniature surface probe and a fine needle probe, respectively. \* p \< 0.05 vs Vehicle at respective time point by One Way ANOVA. Values are mean ± SEM.

In an effort to corroborate these laser doppler flow results, contrast enhanced ultrasound measurements of hindlimb skeletal muscle perfusion were used as an adjunct means of measurement. Figure [4](#Fig4){ref-type="fig"} illustrates the images and data set obtained from a single animal on day 0 immediately following ischemic insult. Panels A and B are images of sagittal sections of the right (nonischemic) and left (ischemic) gastrocnemius muscles, respectively, of the same rat obtained minutes after left femoral artery ligation. Once satisfactory images were obtained, a solution of 3.0x10^8^ microbubbles was administered as an i.v. bolus, and the change in contrast over time was examined. Within a manually defined region of interest (enclosed by the blue outline in panels A and B), the change in contrast intensity was calculated for each frame of captured video and used to create the scatter plot shown in panel C. From the fitted curve of the scatter plot, the plateau and the slope can be calculated. The plateau represents the maximum change in contrast and is an indicator of blood volume, while the slope indicates the rate of change in contrast intensity and reflects the rate of blood flow. Panels D and E are representative illustrations of the changes in blood volume and flow rate, respectively, in the ischemic hindlimb just minutes after femoral artery ligation (generated from the curves in panel C). Total blood volume in the ischemic gastrocnemius of the rodent was decreased to 42% of the volume in the nonischemic limb, consistent with LD flow measurements taken just after the induction of ischemia. Panel E demonstrates a reduction in the rate of blood flow in the ischemic gastrocnemius of greater than 90% compared to the nonischemic muscle just after surgery.Figure 4Contrast Ultrasound Measurements of Hind Limb Perfusion. Panels **A** and **B** are images of the gastrocnemius muscles in the nonischemic and ischemic limbs, respectively, from a single animal minutes after left femoral artery ligation. After microbubble injection, the change in contrast over time can be measured over a manually selected region of interest (ROI) within the image (shown enclosed by a blue line). Panel **C** is a scatter plot of the change in contrast intensity over time derived from the ROIs in panels **A** and **B**. Panels **D** and **E** demonstrate the cumulative changes in contrast intensity and the rates of change in intensity, respectively, which are derived from the best fit curves for the scatter plots in panel **C**.

Figure [5](#Fig5){ref-type="fig"} shows day 14 contrast ultrasound measurements of hindlimb perfusion from the same group of animals from Figure [3](#Fig3){ref-type="fig"}. Panels A-D are representative plots of contrast measurements taken from vehicle, 0.25 mg/kg, 0.5 mg/kg, or 1.0 mg/kg Na~a~S treated rats, respectively, suggesting that sulfide treatment at all 3 doses restores blood volume in the ischemic hindlimb by day 14. Panel E illustrates these results, which paralleled those obtained with both laser doppler flow probes on day 14 (Figures [3](#Fig3){ref-type="fig"}A and B).Figure 5Contrast Ultrasound Perfusion Measurements Corroborate Laser Doppler Measurements. Panels **A**-**D** are representative scatter plots of changes in contrast in the ischemic and nonischemic hindlimbs of a single animal from vehicle, 0.25 mg/kg, 0.5 mg/kg, or 1.0 mg/kg Na~2~S treated cohorts, respectively, after 14 days of treatment. Panel **E** is a comparison of the change in contrast intensity in the ischemic limbs between treatment groups.

Experiment 3 {#Sec12}
------------

A final experiment was designed to determine if the changes in blood flow with Na~2~S treatment persisted after treatment stopped, as well as to attempt to further elucidate a minimum effective dose. To address these questions, 32 animals were divided into 4 groups receiving 0.25 mg/kg sodium sulfide twice daily for 7 days (n = 8), 0.25 mg/kg twice daily for 3 days (n = 8), 0.5 mg/kg once a day for 7 days (n = 8), or vehicle twice daily for 7 days (n = 8). For this experiment, LD blood flow measurements were made pre- and post- ligation on day 0, and then on days 7, 14, and 28. Contrast ultrasound measurements were made on days 14 and 28.

Figure [6](#Fig6){ref-type="fig"} illustrates the results of laser doppler measurements of blood flow from these animals. In animals that were treated with sodium sulfide at 0.25 mg/kg twice daily for 7 days or at 0.5 mg/kg once a day for 7 days, blood flow in the ischemic limb was significantly elevated by day 7. The results of the former treatment group are consistent with laser doppler results from the previous experiment, and the results from rats administered Na~2~S at 0.5 mg/kg suggest that multiple daily administrations are unnecessary. Furthermore, the elevation of blood flow at day 7 was maintained through day 28 in both treatment groups, suggesting that the positive effects of sulfide administration were not transient. Blood flow in the ischemic limbs of animals receiving 0.25 mg/kg twice a day for 3 days was never significantly different from vehicle treated animals at any time point.Figure 67 Day Administration of Na~2~S is Sufficient to Enhance Blood Flow to the Ischemic Hind Limb, which Persists 3 Weeks After Treatment is Stopped. This graph illustrates day 0, 7, 14, and 28 laser doppler blood flow measurements from the ischemic hind limbs of rats treated with either vehicle or Na~2~S at 0.25 mg/kg twice daily for 3 days, 0.25 mg/kg twice daily for 7 days, or 0.5 mg/kg once daily for 7 days. \* p \< 0.05 vs Postligation within the same treatment group by One Way ANOVA. Values are mean ± SEM.

Contrast ultrasound was again used as an alternative means of assessing perfusion in the ischemic hindlimb, this time taking measurements at both day 14 and day 28. Consistent with laser doppler blood flow results, sodium sulfide administered twice daily at 0.25 mg/kg or once daily at 0.5 mg/kg for 7 days significantly elevated the total blood volume delivered to ischemic skeletal muscle. This effect was seen in both treatment groups at day 14 (Figure [7](#Fig7){ref-type="fig"}A) and day 28 (Figure [7](#Fig7){ref-type="fig"}C). While there was a positive impact on blood volume, there was no significant effect on the rate of blood flow (Day 14 -- Figure [7](#Fig7){ref-type="fig"}B, Day 28 -- Figure [7](#Fig7){ref-type="fig"}D).Figure 7Corroboration of Laser Doppler Measurements with Ultrasound. Panels **A** and **B** are contrast ultrasound measurements of relative blood volume and blood flow rate, respectively, at day 14 from the ischemic hindlimbs of rats treated with either vehicle or Na~2~S at 0.25 mg/kg twice daily for 3 days, 0.25 mg/kg twice daily for 7 days, or 0.5 mg/kg once daily for 7 days. Panels **C** and **D** show relative blood volume and flow rate at day 28 from the same animals. \* p \< 0.05 vs Vehicle by One Way ANOVA. Values are mean ± SEM.

Discussion {#Sec13}
==========

In previous reports of the efficacy of sulfide in the hindlimb model, investigators utilized extended treatment periods. Wang et al. treated rats once daily for 4 weeks, while Bir et al. treated mice twice daily for 2 weeks. In the present study, we started with the dosing regimen used by Bir et al. and incrementally decreased the dosing concentration and frequency until we approached an MED. In our hands, we find that sodium sulfide administered intravenously at 0.25 mg/kg twice daily, or at 0.5 mg/kg once daily, for 7 days was sufficient to restore perfusion to ischemic skeletal muscle. Furthermore, this MED was also shown to provide a prolonged effect that was demonstrable at day 28.

In considering techniques for measuring tissue perfusion, intravenous injection of fluorescent microspheres is a cost effective approach, but it is an end point measurement; lacking the capacity for multiple measurements in a single animal. Laser doppler flowmetry affords the ability to noninvasively measure blood flow in the same animal repeatedly. However, shallow penetration allows only very superficial blood flow to be measured, and occlusion of subdermal microvascular blood flow with the probe itself is a concern with non-scanning probes like those used in this study. We therefore used contrast enhanced ultrasound in conjunction with laser doppler measurements. Ultrasound provides an actual image of the tissue that perfusion is being measured in, offers a much better depth of measurement, and circumvents issues with superficial microvascular occlusion. Results of contrast ultrasound perfusion measurements corroborated those using LD flowmetry.

Clinical trials of therapeutic angiogenesis for PAD and CLI have focused on delivery of constructs encoding genes for proangiogenic growth factors like VEGF, FGF, and HGF or certain bone marrow derived progenitor cell populations, with mixed results. The small size of hydrogen sulfide gas, along with its partition coefficient and rapid diffusion in and through lipid membranes \[[@CR29],[@CR30]\], can facilitate its delivery to ischemic tissue despite a diminished or absent blood flow. At physiologic pH (7.4), sulfide exists predominantly as the more hydrophilic hydrosulfide anion (HS^−^), which would be subject to partitioning and is more sensitive to oxidation relative to its fully protonated counterpart. Sulfide becomes increasingly protonated as pH falls, reaching its pKa at 7.0, and then exists predominantly as H~2~S gas at more acidic pH. The acidification of ischemic tissue would only favor sulfide protonation, which should facilitate its delivery within ischemic tissue.

Conclusions {#Sec14}
===========

The results of this study corroborate findings from other labs demonstrating that hydrogen sulfide enhances blood flow and vascular density in the ischemic rat hindlimb when administered at 0.5 and 1.0 mg/kg twice daily over 14 days. The minimum efficacious dose is either 0.25 mg/kg twice daily or 0.5 mg/kg once daily for 7 days. Shortening the treatment window to 3 days was noneffective. Furthermore, these effects appear to be long-lived. These data, together with published results from a number of other labs, lend further credence to the notion that hydrogen sulfide can enhance the vascularity and perfusion of ischemic tissue.
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